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Abstract
Background: N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac
troponin-I (cTnI) are biomarkers commonly evaluated in cats with suspected heart
disease. Many cats with hypertrophic cardiomyopathy (HCM) have systolic anterior
motion of the mitral valve (SAM), but its influence on circulating NT-proBNP or cTnI
concentrations is currently unknown.
Hypothesis/Objectives: Cats with HCM and SAM (HCMSAM+) have higher
NT-proBNP and cTnI concentrations than do cats with HCM but without SAM
(HCMSAM−).
Animals: One hundred forty cats with HCM: 70 with SAM and 70 without SAM.
Methods: Retrospective case-to-case study. Cats were recruited if diagnosed with
HCM by echocardiography and results were available for NT-proBNP or cTnI con-
centrations or both. Cats with SAM were matched to those without SAM for clinical
presentation, left atrial (LA) size and left ventricular (LV) fractional shortening.
Results: A total of 119 NT-proBNP and 123 cTnI results were available. The
HCMSAM+ cats had higher median concentrations than did HCMSAM− cats for
NT-proBNP (729 pmoL/L; interquartile range [IQR], 275-1467 versus 65 pmoL/L;
IQR, 25-271; P < .001) and cTnI (0.27 ng/mL; IQR, 0.10-0.81 versus 0.07 ng/mL;
IQR, 0.01-0.43; P = .002). In general linear models for both NT-proBNP and cTnI, the
independent explanatory variables were SAM, congestive heart failure, maximal LV
wall thickness, and LA size.
Conclusions and Clinical Importance: For cats with HCM and equivalent LA size and
LV systolic function, those with SAM had higher NT-proBNP and cTnI concentrations
than did those without SAM. Presence of SAM should be considered when inter-
preting biomarker concentrations in cats with HCM.
Abbreviations: ATE, aortic thromboembolism; CHF, congestive heart failure; cTnI, cardiac troponin-I; DLVOTO, dynamic left ventricular outflow tract obstruction; FS%, left ventricular fractional
shortening percentage; HCM, hypertrophic cardiomyopathy; HCMSAM+, cats with hypertrophic cardiomyopathy and systolic anterior motion of the mitral valve; HCMSAM−, cats with
hypertrophic cardiomyopathy but without systolic anterior motion of the mitral valve; LA : Ao, left atrium-to-aortic ratio; LAD Max, maximal left atrial diameter; LVIDd, left ventricular internal
diameter in end-diastole; LVIDs, left ventricular internal diameter in end-systole; LVOT Vmax, maximal left ventricular outflow tract velocity; LVWT Max, maximal end-diastolic left ventricular
wall thickness; NT-proBNP, N-terminal pro B-type natriuretic hormone; POC, point-of-care; QMHA, Queen Mother Hospital for Animals; SABP, systolic arterial blood pressure; SAM, systolic
anterior motion of the mitral valve.
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1 | INTRODUCTION
Cardiac biomarkers increasingly have been used in cats with heart
disease. N-terminal pro B-type natriuretic hormone (NT-proBNP) is a
biomarker of myocardial stress and stretch. Its application as a car-
diac biomarker includes screening for preclinical cardiomyopathy,1-4
assessing disease severity,5 and differentiating cardiogenic and non-
cardiogenic causes in cats with dyspnea.4-8 It has been proposed as
being particularly useful for general practitioners without access to
echocardiography.9 Cardiac troponin-I (cTnI) is a biomarker of myo-
cardial injury. Its use as a cardiac biomarker includes assessing car-
diomyopathy severity,10 differentiating cardiogenic and noncardiac
causes in cats with dyspnea,11 and providing additional prognostic
information independent of left atrial size and function, and left ven-
tricular systolic function.12,13
Hypertrophic cardiomyopathy (HCM) is a disease with considerable
morphological and functional variation. For example, there are differ-
ences in segmental versus global concentric hypertrophy,14 presence or
absence of systolic anterior motion of the mitral valve (SAM)15,16 and
mid-ventricular obstruction,17 and papillary muscle morphology varies.15
Of these, SAM is encountered frequently, with a reported prevalence of
approximately 30% in cats with HCM phenotype.18,19 Systolic anterior
motion of the mitral valve is associated with more severe left ventricular
concentric hypertrophy in cats, but whether SAM is an effect or a cause
of the hypertrophy is unknown.15 Cardiac magnetic resonance imaging
studies suggest that abnormalities of both left ventricular geometry and
the mitral valve apparatus likely contribute to the origin of SAM in peo-
ple.20 Similar abnormalities likely occur in affected cats.15
Although the primary stimulus for release of NT-proBNP is myocar-
dial stretch, other conditions that result in increased wall stress or ven-
tricular hypertrophy have been found to increase plasma concentrations
of NT-proBNP.21-25 Dynamic left ventricular outflow tract obstruction
(DLVOTO) would be expected to increase myocardial wall stress, and
therefore increase NT-proBNP.26,27 Furthermore, DLVOTO has been
associated with an increased risk of myocardial ischemia in people with
HCM, which would be expected to result in increased cTnI concentra-
tions.26,28 Many studies have shown that NT-proBNP and cTnI concen-
trations are increased in cats with HCM phenotype,2,5,10,12,29 but
whether or not the presence of SAM further increases these biomarker
concentrations currently is unknown.
2 | AIMS/OBJECTIVES
The first aim of our study was to compare circulating concentrations
of NT-proBNP and cTnI in cats with HCM phenotype and SAM as
compared to cats with HCM phenotype but without SAM. The second
aim was to create multivariable models to identify factors associated
with variation in NT-proBNP and cTnI concentrations. We hypothe-
sized that cats with SAM would have higher NT-proBNP and cTnI
concentrations than cats at a similar stage of HCM without SAM, and
that this relationship would be independent of other factors when
assessed in a multivariable model.
3 | MATERIALS AND METHODS
3.1 | Study design
This study is a retrospective case-to-case study design. Ethical
approval was provided by the Royal Veterinary College (URN:
SR2019-0245). Electronic medical records between December
2011 and May 2018 from the Queen Mother Hospital for Small
Animals (QMHA) and a cardiac screening study at rehoming cen-
ters for cats (the CatScan study18) were reviewed for cats diag-
nosed with HCM and with NT-proBNP, cTnI, or both measured.
The diagnosis of HCM was defined as left ventricular hypertrophy
at any region measuring ≥6 mm on 2-dimensional (2D) imaging.16
For each case, medical records corresponding with the time of
biomarker measurement were reviewed. The signalment, medical his-
tory, physical examination findings, systemic arterial blood pressure
(SABP) measurements using Doppler technique, presence of conges-
tive heart failure (CHF), arrhythmias or aortic thromboembolism (ATE),
and current medications were recorded. Where the intensity of a murmur
varied, the highest murmur grade was recorded. Cats were excluded if they
were diagnosed with dehydration, hyperthyroidism, SABP ≥ 180 mm Hg,30
diabetes mellitus, cardiomyopathies with phenotype other than HCM, car-
diac neoplasia, congenital heart disease, anemia (packed cell volume <20%),
or had incomplete clinical records. Cats with serum creatinine concentra-
tions ≥2.9 mg/dL (≥251 μmol/L) or ≥1.6 mg/dL (≥140 μmol/L) without
SABP measurement also were excluded.30
Echocardiograms matching the dates of the biomarker measurement
were reviewed by a single observer (J.S.). All echocardiographic measure-
ments were taken over 3 different cardiac cycles and averaged. After con-
firming the diagnosis, the presence of SAM was assessed with frame-by-
frame review of the 2D imaging of a right parasternal 5-chamber view,
optimized for the left ventricular outflow tract (LVOT).15 Systolic anterior
motion of the mitral valve was defined as anterior motion of either septal
or both mitral valve leaflets during systole toward the LVOT on review of
the 2D cineloop.31 Other echocardiographic variables were measured by
the same investigator (J.S.) as described in Table 1. These
included: left atrium to aortic ratio (LA : Ao),32 maximal left atrial
diameter (LAD Max),33,34 maximal left ventricular wall thickness
(LVWT Max),34 left ventricular internal diameter in end-diastole
(LVIDd) and end-systole(LVIDs),35 left ventricular fractional
shortening (FS%),35 and maximal LVOT velocity (LVOT Vmax).16
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Dynamic left ventricular outflow tract obstruction was defined as
LVOT Vmax ≥2.5 m/s in the absence of echocardiographic evi-
dence of fixed aortic stenosis.15,16 Regional wall hypokinesis was
defined as asynchronous motion or minimal excursion of a myo-
cardial segment compared with the adjacent segment.12,36
3.2 | Matching process
The case-to-case groups (HCMSAM+ and HCMSAM−) were created
starting with all cats without SAM (HCMSAM−), and calculating the
proportion of cats with CHF, ATE and arrhythmias, and the mean or
median of the echocardiographic variables (LAD Max, LA : Ao, LVIDd,
LVIDs, and FS%). Cats with SAM were introduced 1 cat at a time to a
HCMSAM+ group, to create a group with characteristics matching the
HCMSAM− group. As described in the introduction, LVWT Max was
expected to be higher in the HCMSAM+ group, and no attempt was
made to match this variable between the groups.15
3.3 | NT-proBNP and cTnI measurements
An EDTA blood sample was collected for a second-generation
NT-proBNP assay. The NT-proBNP samples were processed by
TABLE 1 Echocardiographic variables of interest
Echocardiographic variable View and timing Measurement
LA : Ao32 View: RPSAX at the level of the aortic valve
Imaging modality: 2D Imaging
Timing: Beginning of diastole, the first frame of aortic valve closure
Ao: From the blood-tissue interface at
the midpoint of the right aortic sinus
to the commissure between the
noncoronary and left coronary aortic
cusps
LA: Extension of the aortic line to the
blood-tissue interface of the left atrial
wall, immediately lateral to the
pulmonary vein
LAD Max33,34 View: RPLAX4ch
Imaging modality: 2D Imaging
Timing: Beginning of diastole, the last frame before the mitral valve
opening
Mid-interatrial septum to the leading
edge of the pericardium, bisecting the
left atrium parallel to the mitral valve
annulus
LVWT Max34 View: RPLAX4ch, RPLAX5ch, and RPSAX at the level of the papillary
muscles
Imaging modality: 2D Imaging
Timing: End-diastole, the last frame before the aortic valve opens
(RPLAX5ch), the first frame after the mitral valve closes (RPLAX4ch), or
when the left ventricular internal diameter was the largest (RPSAX)
Leading edge technique avoiding the
papillary muscles or false tendon
attachments
Only the average of 3 measurements
from the area that measures the
maximal thickness is used
LVIDd35 View: RPSAX at the level of the papillary muscles
Imaging modality: 2D Imaging
Timing: End-diastole
Leading edge technique bisecting the left
ventricle in end-diastole
LVIDs35 View: RPSAX at the level of the papillary muscles
Imaging modality: 2D Imaging
Timing: End-systole
Leading edge technique bisecting the left
ventricle in end-systole
FS%35 – Calculated using (LVIDd−LVIDs)/LVIDd
LVOT Vmax16 View: LA5ch with the cursor transecting the left ventricular outflow tract.
Imaging modality: Spectral Doppler (either pulse wave or continuous
wave) imaging
Timing: Systole, when the modal velocity was the greatest
Maximal modal velocity in systole was
recorded. The measurement was not
recorded when there was inadequate
cursor alignment, absence of a
dynamic profile, or contamination of
the mitral regurgitation
DLVOTO15,16 – Defined as LVOT Vmax ≥2.5 m/s
Regional wall
hypokinesis12,36
View: Overview of the RPLAX4ch, RPLAX5ch, RPSAX, LA4ch, LA5ch
Imaging modality: 2D Imaging
Timing: Across the entire cardiac cycle
Subjective recognition of a segment with
asynchronous motion to the adjacent
segment or minimal in excursion on 2D
imaging
Note: All echocardiographic measurements in this study were taken over 3 different cardiac cycles and averaged.
Abbreviations: DLVOTO, dynamic left ventricular outflow tract obstruction; FS%, left ventricular fractional shortening; LA:Ao, left atrium to aortic ratio;
LA4ch, left apical 4-chamber view, LA5ch, and 5-chamber view; LAD Max, maximal left atrial diameter; LVIDd, left ventricular internal diameter in diastole,
LVIDs, and systole; LVOT Vmax, maximal left ventricular outflow tract velocity; LVWT Max, maximal end-diastolic left ventricular wall thickness;
RPLAX4ch, right paraternal long axis 4-chamber view, RPLAX5ch, and 5-chamber view; RPSAX, right parasternal short axis view.
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2 different methods, both after the instructions of the reference
laboratory (IDEXX Veterinary Laboratories, Wetherby, Workshire,
United Kingdom): For the samples taken at the QMHA, the samples
were centrifuged at 800g for 3 minutes and plasma was transferred to
a separate plain tube and refrigerated at 4!C. The samples then were
transported within 24 hours to the reference laboratory where the
assays were performed. For samples collected at the rehoming cen-
ters, samples were centrifuged at 4000 rpm for 15 minutes. Plasma
was separated and immediately frozen at −20!C. Batches of frozen
samples were transferred on dry ice to the reference laboratory and
underwent batch analysis.
Cardiac troponin-I was analyzed using 2 different analyzers: For
all samples from the rehoming centers and for some from the QMHA,
a blood sample was collected in a plain tube and processed in an iden-
tical manner as samples for the NT-proBNP assay. These samples then
were analyzed at the reference laboratory. Some cats from the QMHA
had a point-of-care (POC) high sensitivity cTnI measurement per-
formed with a handheld analyzer (VetScan i-STAT Analyzer, Abaxis,
Abbott Point of Care Inc, Union City, California). Either whole blood in
plain tubes or heparinized whole blood samples were used immedi-
ately or within 10 minutes after collection, respectively.
The lower and upper limits of detection for NT-proBNP were
24 and 1500 pmoL/L, respectively. Results reported as <24 or
>1500 pmoL/L were entered as 23 or 1501 pmoL/L, respectively, for
statistical analysis. The high sensitivity cTnI assay from the reference
laboratory had a lower limit of detection of 0.01 ng/mL and no upper
limit. The POC analyzer had the same lower limit of detection but an
upper limit of 50 ng/mL. Results reported as <0.01 ng/mL were
entered as 0.009 ng/mL. The POC results >50 ng/mL were entered as
51 ng/mL.
4 | STATISTICAL ANALYSIS
Commercial software programs were used for statistical analysis (IBM
SPSS Statistics Version 24) and generating graphs (GraphPad Prism
7 Version 7.0d). Normality of the continuous variables was tested
visually and by a Shapiro-Wilk test. Normally distributed data are
presented as mean (±SD) and non-normally distributed data as median
(interquartile range, IQR). Continuous variables were compared using
either an independent t test or Mann-Whitney test. Categorical
demographic variables were compared by a Pearson chi-squared test,
with posthoc analysis done by analyzing the standardized residuals.
Significance was set at P < .05.
The association between the dependent variables (NT-proBNP
and cTnI) and others was tested first by univariable analysis, by either
Pearson's or Spearman's test for continuous variables, and either an
independent t test or Mann-Whitney test for categorical variables.
Significantly associated variables with P < .25 then were selected for
multivariable analysis.
Multivariable analysis was performed by constructing a separate
general linear model for NT-proBNP and cTnI. Both models were cre-
ated in a backward stepwise manner, starting with all significant
variables from the univariable analysis (P < .25) and then removing
non-significant variables 1 at a time until only significant variables
remained (P < .05). Variables were log-transformed if the distribution
was severely skewed, and the residuals of each model were visually
inspected by quantile plots, ensuring the assumption of normal distri-
bution of linear models. Collinearity statistics were checked and
multicollinearity was eliminated.
5 | RESULTS
A total of 210 cats met the initial inclusion criteria. Of these, 70 cats
subsequently were excluded because of anemia (1), limited echocar-
diographic study (8), lymphoma (1), incomplete medical records (23),
hyperthyroidism (3), diabetes mellitus (2), serum creatinine concentra-
tion ≥2.9 mg/dL (8), serum creatinine concentration ≥1.6 mg/dL with
unavailable blood pressure measurement (4), and any additional cats
after matching the 2 groups (20). This process resulted in a final num-
ber of 140 enrolled cats: 40 cats from rehoming centers and 100 cats
from the QMHA. In total, 119 measurements were available for
NT-proBNP, and 123 measurements for cTnI. These cats were divided
into HCMSAM+ (70 cats) and HCMSAM− groups (70 cats; Table 2).
No significant differences in breed, sex, medications, or the pro-
portion of cats with CHF, ATE, or arrhythmias were found between
the groups. Cats in the HCMSAM+ group were significantly younger
(P < .001) with lower body weight (P < .001) than cats in the HCMSAM
− group. A significant difference in presenting complaints was found
between the 2 groups, with most HCMSAM+ cats being presented for
a heart murmur (P < .001) and most HCMSAM− cats being presented
for HCM screening (P < .001). Additional demographic information is
outlined in Table 2.
Based on the study design, no differences were found in LAD Max,
LA : Ao, LVIDd, LVIDs, and FS%. The LVWT Max was higher in the
HCMSAM+ cats (P < .001). Forty-nine of 65 HCMSAM+ cats (68.4%) had
DLVOTO at the time of examination, with a mean LVOT Vmax of
3.3 ± 1.2 m/s. Additional echocardiographic data are presented in Table 3.
Plasma NT-proBNP concentrations were significantly higher in
the HCMSAM+ group (729 pmoL/L [IQR, 275-1467] versus 65 pmoL/L
[IQR, 25-271] in the HCMSAM- group; P < .001; Figure 1). Circulating
concentrations of cTnI also were significantly higher in the HCMSAM+
group (0.27 ng/mL [IQR, 0.10-0.81] versus 0.07 ng/mL [IQR,
0.01-0.43] in the HCMSAM- group; P = .002). This increase was
observed in both the non-DLVOTO and DLVOTO populations of the
SAM group (P = .3 for NT-proBNP and P = .6 for cTnI comparing non-
DLVOTO and DLVOTO subgroups).
Results of the univariable analysis are summarized in TableS1.
Using these results, the following variables were tested in a general
linear model to explain the variation of NT-proBNP: source population
(QMHA versus rehoming centers), presenting complaint, age, body
weight, body condition score, breed, SABP, murmur grade, gallop
sound, sedation, medication, urea, creatinine, CHF, ATE, arrhythmias,
SAM, DLVOTO, LVOT Vmax, LVIDs, FS%, LVWT Max, LAD Max,
regional wall hypokinesis, and cTnI. Similarly, the following variables
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TABLE 2 Demographic characteristics for the 140 cats with hypertrophic cardiomyopathy
HCMSAM+ (n = 70) HCMSAM− (n = 70) P value
Population
CatScan 9 (12.9%) 31 (44.3%) <.001
QMHA 61 (87.1%) 39 (55.7%)
Age (years) 4.1 [2.4-7.0] 6.9 [4.0-10.6] <.001
Weight (kg) 4.4 (±1.0) 5.2 (±1.2) <.001
BCS (/9) 5.0 [4.0-5.0] 5.0 [5.0-6.4] .332
Presenting complaint (%) <.001
Arrhythmias 0 1 (1.4%)
Collapsing episodes 3 (4.3%) 2 (2.9%)
Gait abnormality 4 (5.7%) 5 (7.1%)
Murmur 32 (45.7%) 8 (11.4%)
Respiratory signs 7 (10%) 9 (12.9%)
HCM screening 13 (18.6%) 39 (55.7%)
HCM reassessment 11 (15.7%) 6 (8.6%)
Murmur (%) 66/68 (94.3%) 42/69 (60.9%) <.001
Murmur grade 3 [3-4] 2 [0-3]
Gallop sound (%) 3/26 (11.5%) 8/57 (11.4%) 1.000
Arrhythmiasa 5 (7.1%) 8 (11.4%) .562a
Congestive heart failurea 8 (11.4%) 13 (18.6%) .344a
Aortic thromboembolisma 3 (4.3%) 3 (4.3%) 1.000a
Sex
Female (%) 25 (35.7%) 21 (30.0%) .590
Neutered : Entire 22:3 18:3
Male (%) 45 (64.3%) 49 (70.0%)
Neutered : Entire 42:3 42:7
Number of pedigree cats (%) 15 (21.4%) 20 (28.6%) .255
Bengal 2 (2.9%) 2 (2.9%)
British Short Hair 3 (4.3%) 2 (2.9%)
Domestic Long Hair 5 (7.1%) 6 (8.6%)
Domestic Medium Hair 2 (2.9%) 1 (1.4%)
Domestic Short Hair 48 (68.6%) 43 (61.4%)
European Short Hair 3 (4.3%) 0
Maine Coon 0 1 (1.4%)
Norwegian Forest Cat 1 (1.4%) 8 (11.4%)
Persian 2 (2.9%) 1 (1.4%)
Russian Blue/White 1 (1.4%) 2 (2.9%)
Scottish Fold 1 (1.4%) 1 (1.4%)
Siamese 0 2 (2.9%)
Sphynx 2 (2.9%) 1 (1.4%)
Doppler blood pressure 124.1 (±18.8) (n = 41) 129.7 (±21.6) (n = 39) .224
Renal markers
Urea (mg/dL) 27.2 [21.8-39.2] (n = 14) 28.3 [25.8-35.6] (n = 35) .603
Creatinine (mg/dL) 1.52 (±0.28) (n = 16) 1.58 (±0.35) (n = 35) .618
Medications (number of cats) 6 (8.6%) 4 (5.7%) .512
Aspirin 0 1 (1.4%)
Atenolol 1 (1.4%) 0
(Continues)
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TABLE 2 (Continued)
HCMSAM+ (n = 70) HCMSAM− (n = 70) P value
Benazepril 2 (2.9%) 2 (2.9%)
Clopidogrel 3 (4.3%) 1 (1.4%)
Diltiazem 1 (1.4%) 0
Furosemide 4 (5.7%) 4 (5.7%)
Pimobendan 0 1 (1.4%)
Note: The cats were divided in 2 groups: Hypertrophic cardiomyopathy with systolic anterior motion of the mitral valve (HCMSAM+) and hypertrophic car-
diomyopathy without systolic anterior motion of the mitral valve (HCMSAM−).
aActively matched variables.
TABLE 3 Echocardiographic variables and cardiac biomarker results for the 140 cats with hypertrophic cardiomyopathy
HCMSAM+ (n = 70) HCMSAM− (n = 70) P value
SAM 70 (100%) 0
Sedation 1 (1.4%) 2 (2.9%) 1.000
LVOT Vmax (m/s) 3.3 (±1.2) (n = 65) 1.1 (±0.5) (n = 29) <.001
DLVOTO 49/65 (68.4%) 0/50 (0%) <.001
LAD Max (mm)a 16.4 [14.5-17.9] 15.4 [13.7-17.4] .163a
LA : Aoa 1.3 [1.2-1.5] 1.3 [1.2–1.5] .762a
LVIDd (mm)a 13.9 [12.5-15.4] 14.2 [12.5-16.1] .216a
LVIDs (mm)a 5.0 [3.9-5.9] 5.6 [3.8-7.2] .115a
FS%a 62.4 [57.6-71.4] 61.9 [50.2-69.9] .253a
Regional wall hypokinesis 5 (7.1%) 6 (8.6%) 1.000
LVWT Max (mm) 7.2 [6.6-8.2] 6.5 [6.1-6.8] <.001
NT-proBNP (pmoL/L) 729 [275–1467] (n = 61) 65 [25–271] (n = 58) <.001
cTnI (ng/mL) 0.27 [0.10–0.81] (n = 59) 0.07 [0.01–0.43] (n = 64) .002
POC cTnI 7/59 (11.9%) 7/64 (10.9%) 1.000
Abbreviations: DLVOTO, dynamic left ventricular outflow tract obstruction; FS%, fractional shortening %; LA : Ao, left atrium-to-aortic ratio; LAD Max,
maximal left atrial diameter; LVIDd, LVIDs, left ventricular internal diameter in diastole and systole; LVOT Vmax, maximal left ventricular outflow tract
velocity; LVWT Max, maximal left ventricular wall thickness; SAM, systolic anterior motion of the mitral valve.
aActively matched variables.
F IGURE 1 Box and whisker
plots graphs comparing plasma
concentrations of A, NT-proBNP
and B, cTnI in cats with
hypertrophic cardiomyopathy
with and without systolic
anterior motion of the mitral
valve (groups HCMSAM+ and
HCMSAM−, respectively). cTnI,
cardiac troponin-I; HCMSAM
+/HCMSAM−, cats with
hypertrophic cardiomyopathy
and with/without systolic
anterior motion of the mitral
valve; NT-proBNP, N-terminal
pro B-type natriuretic peptide
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were tested for cTnI: source population, presenting complaint, body
weight, body condition score, SABP, gallop sound, sedation, medica-
tion, urea, CHF, ATE, arrhythmias, SAM, DLVOTO, LVOT Vmax,
LVIDs, FS%, LVWT Max, LAD Max, regional wall hypokinesis, POC
cTnI, and NT-proBNP. Because of their skewed distribution, NT-
proBNP and cTnI were log-transformed for further analysis.
Results of multivariable analysis are presented in Table 4. For
both general linear models, LAD Max, CHF, SAM, and LVWT Max
were the final independent variables with an adjusted R2 of .52 for
NT-proBNP and .49 for cTnI. The beta coefficient for SAM was higher
than for LVWT Max in both models. Other variables including age,
source population (QMHA versus rehoming centers), POC cTnI, creat-
inine, urea, SABP, and presence of regional wall hypokinesis were not
significant in either model. Visual inspection of the residuals was con-
sistent with good model fit.
6 | DISCUSSION
We compared cardiac biomarker concentrations in cats with HCM
and SAM to those without SAM that were otherwise similar for sex,
breed, left atrial and left ventricular size, clinical signs, blood pressure,
and renal markers. Concentrations of circulating NT-proBNP and cTnI
were significantly higher in the cats with SAM, and multivariable anal-
ysis confirmed that presence of SAM was associated with higher
NT-proBNP and cTnI concentrations, independent of other factors.
Left atrial size is widely considered 1 of the most important prog-
nostic factors in cats with cardiomyopathy,31,36,37 and although
NT-proBNP also has been shown to have prognostic value, at least
1 study has shown left atrial size to be a more important indicator.12
In situations where echocardiography is unavailable, NT-proBNP con-
centrations sometimes are measured as a means of screening for more
advanced disease. We were not able to determine whether the higher
NT-proBNP concentrations in the cats with SAM corresponded with a
worse prognosis, but we were able to show that cats with SAM can
have high NT-proBNP even with normal left atrial size. Approximately
one-third of cats with HCM phenotype have SAM on
presentation,18,19 and our findings suggest that the presence or
absence of SAM should be taken into consideration when interpreting
NT-proBNP concentrations.
Other independent explanatory variables in our final multivariable
model of NT-proBNP were LAD Max, CHF, and LVWT Max. These find-
ings are expected based on previous studies that showed increased NT-
proBNP concentrations with ventricular hypertrophy, left atrial enlarge-
ment, and CHF.1-9,25 Renal disease and systemic hypertension are other
known conditions associated with increased NT-proBNP concentrations
in cats.30 These variables were not significant in our final multivariable
model, likely because of our study design in which cats with systemic
hypertension and azotemia were excluded.
Cardiac troponin-I also was higher in cats with SAM. In people,
SAM is thought to confer greater risk of myocardial ischemia as a result
of increased myocardial oxygen demand and decreased coronary perfu-
sion, potentially associated with worsening hypertrophy, microvascular
dysfunction,26,38,39 and arteriolosclerosis of intramural small coronary
arteries.38,39 Similar mechanisms are hypothesized in cats with HCM
and SAM. The higher cTnI concentrations in cats with HCM have been
associated with shorter survival times,12,13 but studies to date have
failed to show any association between the presence of SAM and
increased cardiac morbidity or mortality in cats.16,19,36,40,41 These obser-
vation contrast with those of human medical literature in which SAM is
considered a negative prognostic factor in HCM.26 In our study and in
other studies, cats with HCM and SAM were younger than cats without
SAM. The recent REVEAL study showed similar survival times between
cats with obstructive and nonobstructive HCM, but cats with obstruc-
tive HCM also were younger than cats with nonobstructive HCM.19
Other significant independent explanatory variables in our study were
LAD Max, CHF, and LVWT Max, findings that are similar to those of
previous studies.10,11
TABLE 4 Two multivariable models with NT-proBNP and cTnI as dependent variables after log-transformation
1. log(NT-proBNP)
Adjusted R2 = .524 B coefficient (95% CI) Standardized B coefficient P value
CHF 0.496 (0.209-0.783) 0.229 .001
SAM 0.583 (0.398-0.767) 0.448 <.001
LAD Max 0.050 (0.025-0.076) 0.268 <.001
LVWT Max 0.137 (0.038-0.236) 0.208 .007
2. log(cTnI)
Adjusted R2 = .493 B coefficient (95% CI) Standardized B coefficient P value
CHF 1.060 (0.694-1.425) 0.407 <.001
SAM 0.436 (0.188-0.685) 0.237 .001
LAD Max 0.070 (0.038-0.102) 0.309 <.001
LVWT Max 0.169 (0.050-0.288) 0.196 .006
Abbreviations: CHF, congestive heart failure, cTnI, cardiac troponin-I; LAD Max, maximal left atrial diameter; LVWT Max, maximal left ventricular wall
thickness; NT-proBNP, N-terminal pro B-type natriuretic peptide; SAM, systolic anterior motion of the mitral valve.
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Systolic anterior motion of the mitral valve usually is associated
with DLVOTO, which can result in increased left ventricular wall
stress and ischemia.26,42 However, although the presence of SAM
was a statistically significant explanatory variable for both
NT-proBNP and cTnI in our study, neither LVOT Vmax nor the
presence of DLVOTO was significant in our general linear models.
We defined DLVOTO as LVOT velocities >2.5 m/s, although to
confirm the site of dynamic obstruction, color Doppler imaging is
necessary to show variance and aliasing in the LVOT and an eccen-
tric jet of mitral regurgitation. Dynamic LVOT obstruction is known
to be labile, and is affected by loading conditions and sympathetic
tone.43 Provocative maneuvers often are used to provoke a gradi-
ent across the LVOT in people with HCM,44 and auditory stimula-
tion sometimes is used in cats with HCM for this purpose. It is
difficult to standardize echocardiographic conditions in cats, and
the echocardiographic examination itself could be considered a
provocative maneuver, with variable effects in different cats. The
magnitude of LVOT gradient that should be considered clinically
relevant in cats with HCM has not been established, nor whether
or not this conclusion should be based on a resting or provoked
gradient. It is not clear why SAM has a closer association with
NT-proBNP and cTnI concentrations than with presence of
DLVOTO or LVOT Vmax. It might reflect greater ease of recording
SAM compared with DLVOTO or LVOT Vmax, or that SAM is more
consistently present in cats with intermittent LVOT obstruction.
Our study had a number of limitations, many of which were a
consequence of its retrospective nature. First, the NT-proBNP sam-
ples were processed by 2 different methods according to the
instructions provided by the reference laboratory. However, no sig-
nificant effect was seen when using the general linear model with
the variable “population source.” Similarly, cTnI concentrations
were measured using 2 different analyzers, following the instruc-
tions provided by either the reference laboratory or the manufac-
turer of the POC cTnI analyzer. Although this POC cTnI assay has
not been validated in cats, cTnI is well conserved across species
and statistical analysis with or without these cats showed no effect
of including this unvalidated assay in our results, and no significant
effect of the POC cTnI was found in the final models. We elected
to include the cats with cTnI analyzed on the POC assay because
doing so resulted in better balancing of the 2 groups. The HCMSAM
+ cats were younger and had higher LVWT Max. Systemic hyper-
tension previously has been shown to result in left ventricular
hypertrophy in cats.45 Although strict exclusion criteria were
followed, systemic blood pressure recordings were not available in
all cats, and some cats with systemic hypertension inadvertently
may have been included. However, SAM still had a significant influ-
ence on both NT-proBNP and cTnI concentrations independent of
wall thickness, and the influence of age was not significant in the
final multivariable model. Finally, no attempt was made to evaluate
outcome. Doing so was not an aim of our study, and therefore we
cannot determine whether increased NT-proBNP and cTnI
concentrations in cats with SAM are associated with a worse prog-
nosis regardless of left atrial size.
7 | CONCLUSIONS
Cats with HCM and SAM had higher NT-proBNP and cTnI concentra-
tions than did cats without SAM. The presence of SAM should be
taken into consideration when interpreting NT-proBNP and cTnI
results in cats with HCM phenotype.
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